Last reviewed · How we verify
Dasatinib and blinatumomab
Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.
Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3. Used for Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML).
At a glance
| Generic name | Dasatinib and blinatumomab |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Drug class | Tyrosine-kinase inhibitor and Bispecific monoclonal antibody |
| Target | BCR-ABL, c-KIT, PDGFRβ, CD19, CD3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Dasatinib works by binding to the ATP-binding site of its target kinases, thereby inhibiting their activity. Blinatumomab, on the other hand, binds to CD19 on cancer cells and CD3 on T cells, bringing them together to induce T cell-mediated killing of cancer cells.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Chronic myeloid leukemia (CML)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Headache
- Diarrhea
Key clinical trials
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (PHASE2)
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma (PHASE2)
- Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (PHASE1)
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: